Q2 net sales grew 4.8% year-over-year to $2.177 billion, with adjusted EPS steady at $2.07. Full-year 2026 revenue and adjusted EPS guidance were raised, reflecting strong performance and innovation momentum. Share repurchases and FDA clearances marked key developments.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.